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Introdução 
A hiperplasia adrenal congênita (HAC) engloba um grupo de doenças de 
herança autossômica recessiva e que se caracteriza pelo comprometimento da 
esteroidogênese adrenocortical 
(1)
. Os mecanismos fisiopatológicos desta doença foram 
melhores esclarecidos quando a sua natureza genética foi desvendada e as anormalidades 
hormonais caracterizadas na década de 1950 
(1,2)
. Mais de 90% dos casos de HAC 
decorrem de mutações do gene que codifica a enzima 21-hidroxilase (CYP21A2).  
Como o defeito fundamental na HAC por deficiência de 21-hidroxilase 
(D21OH) ocorre na síntese de cortisol, a elevação subsequente do ACTH torna as adrenais 
hiperplásicas e hiperestimuladas, produzindo um excesso de precursores esteróides e 
hormônios sexuais que não requerem 21-hidroxilação para sua síntese. Como 
conseqüência, a manifestação clínica principal da D21OH é a virilização desde o período 
intra-uterino com desenvolvimento de genitália ambígua em meninas e macrogenitossomia 
em meninos, além de crescimento somático acelerado e fusão epifisária prematura em 
ambos os sexos. 
Aproximadamente 75% dos pacientes também são incapazes de sintetizar 
aldosterona em níveis suficientes para manutenção do balanço hidro-eletrolítico, 
predispondo-os ao desenvolvimento de desidratação e choque hipovolêmico e óbito. Essas 
são formas mais graves denominadas de “perdedoras de sal” (PS). Àqueles pacientes com 
virilização pré-natal e níveis elevados de precursores esteróides, mas com produção 
preservada de aldosterona, dá-se o nome de forma “virilizante simples” (VS). Tanto a PS 
com a VS são reconhecidas como “formas clássicas” da doença (2,3).  
A forma não clássica (NC) manifesta-se mais tardiamente e de maneira mais 
leve, com sinais e sintomas mais discretos de hiperandrogenismo desde a infância até a 
vida adulta. A forma NC pode ser também assintomática, sendo comumente detectada 
apenas durante investigação bioquímica e ou molecular de familiares de indivíduos 
afetados 
(2-5)
.  
Por fim, os heterozigotos são indivíduos carreadores de mutações do gene 
da CYP21 presentes em apenas um dos alelos. Apesar de assintomáticos 
(6,7)
, alguns 
estudos mostram uma prevalência maior de hirsutismo ou acne em mulheres dessa 
população 
(8-10)
.  
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A atividade residual da enzima 21-hidroxilase (21OH) reflete as mutações 
do gene da CYP21A2, existindo uma correlação genótipo-fenótipo significativa nos casos 
de D21OH 
(11)
. Os genótipos do grupo A, que resultam em atividade enzimática nula, estão 
relacionados com o fenótipo PS. Nas mutações moderadas, ou com genótipo do grupo B, a 
atividade residual da 21OH é de cerca de 3-7%, resultando nas formas VS. Já nas mutações 
consideradas leves, ou genótipo do grupo C, a atividade enzimática é de 20-50%, sendo 
relacionadas às formas NC 
(2,4,11)
.  
Como uma grande parcela dos indivíduos afetados é de heterozigotos 
compostos (mutações diversas nos diferentes alelos), seu fenótipo reflete o alelo com 
mutação mais leve 
(2,11)
. Por isso, apesar da D21OH ter padrão de herança autossômico 
recessivo, não obedece a um “padrão mendeliano” exato. Deste modo, o emprego do termo 
“heterozigoto” para indivíduos que carreiam apenas um alelo mutante, é inadequado. 
Mesmo assim, por já estar consagrada em textos médicos, manteremos essa terminologia, 
até por que o emprego dos termos “carreadores” ou “portadores” pode causar até maior 
confusão. 
Estudos de rastreamento neonatal mostram que a incidência das formas 
clássicas (PS e VS) pode variar de 1:10.000 a 1:18.000 nascimentos vivos 
(2)
. Recente 
estudo estimou a incidência da forma clássica no Brasil em 1:10.325 nascidos vivos 
(12)
. No 
entanto, a forma NC é muito mais prevalente, e atinge aproximadamente 0,1% da 
população geral 
(2)
, com maior incidência entre os judeus Askenazi (1:27 indivíduos). 
Outros grupos com alta freqüência incluem os hispânicos (1:40), eslavos (1:50) e ítalo-
americanos (1:300) 
(4, 13)
. Esses dados comprovam que a forma NC é a doença de padrão 
autossômico recessiva mais comum no homem 
(2, 4)
. A frequência de heterozigotos para a 
forma clássica da D21OH é de 1:60 indivíduos, enquanto para a forma NC estima-se que 
seja de 1:16 indivíduos, podendo chegar a até 1:3 em judeus do leste europeu 
(4,13-15)
.  
O marcador bioquímico da D21OH é a 17-hidroxiprogesterona (17OHP), 
precursor imediato da 21OH; assim, o diagnóstico da D21OH fundamenta-se na elevação 
de seus níveis séricos 
(1-3)
. Níveis basais elevados da 17OHP são diagnósticos para as 
formas clássicas da D21OH; porém, geralmente são insuficientes para o diagnóstico da 
forma NC. Para isso, a dosagem de 17OHP após 60 minutos da administração intravenosa 
de ACTH sintético (cosintropina) mostra-se essencial para caracterização desse grupo de 
pacientes.  
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O valor de corte tradicionalmente utilizado para os níveis de 17OHP após 
estímulo com ACTH é de 1.000 ng/dL (instituído num período prévio à avaliação do gene 
da CYP21). Valores acima desse limite de corte são compatíveis com a forma NC 
(4,16)
, 
enquanto valores abaixo não discriminariam entre heterozigotos e indivíduos da população 
normal. No entanto, com a introdução da genotipagem da CYP21A2, Azziz et al 
(6)
 e 
Bachega et al 
(17)
, propuseram valores diagnósticos mínimos de 17OHP após estímulo com 
ACTH respectivamente de 1.500 e 1.700 ng/dL para a forma NC. Assim, valores limites 
precisos de 17OHP para diagnóstico da forma NC da D21OH ainda não foram 
definitivamente estabelecidos.  
Estudos prévios mostraram correlação significativa entre genótipo e níveis 
de 17OHP nas diferentes formas de D21OH, com valores mais elevados nas formas 
clássicas, seguidos da forma NC e heterozigotos. Dentre a forma NC, alelos com mutações 
graves (genótipo A/C) apresentam níveis mais elevados de 17OHP após-ACTH, do que 
aqueles com mutações mais leves (genótipo C/C) 
(17,18)
. Em heterozigotos, não há 
correlação entre os níveis de resposta da 17OHP após-ACTH com mutações do gene 
CYP21 no alelo afetado 
(19)
.  
Como a D21OH é uma doença de morbidade importante e de apresentação 
clínica variável (desde assintomática até evolução para óbito), a detecção de heterozigotos 
e o aconselhamento genético aos familiares de risco, principalmente em populações de 
maior incidência, torna-se crítico.  
Apesar de a biologia molecular permitir a identificação dos heterozigotos, a 
genotipagem é pouco disponível e de custo elevado; por isso, o emprego de marcador 
bioquímico poderia facilitar a triagem diagnóstica dessa população. O emprego da 
dosagem sérica da 17OHP para detecção de heterozigotos não apresenta boa precisão 
diagnóstica pela grande sobreposição de valores basais e estimulados (20-70%) com a 
população normal 
(20-24)
.  
Por outro lado, o 21-deoxicortisol (21DF) é um esteróide originado de uma 
via alternativa resultante da11 -hidroxilação da 17OHP no córtex adrenal. Essa via é 
praticamente inativa em indivíduos normais, porém assume importância nos pacientes com 
D21OH 
(25)
. Louriax et al 
(26)
 foram os primeiros a reportar níveis elevados de 21DF em 
pacientes com D21OH, e estudos posteriores confirmaram o papel da dosagem sérica do 
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21DF na detecção de “heterozigotos” para a D21OH (27). Fiet et al (28-30) documentaram que 
os níveis de 21DF em resposta ao estímulo com ACTH mostram sensibilidade próxima de 
100% na detecção dessa população. Portanto, o 21DF após-ACTH poderia ser utilizado 
como um “marcador” bioquímico eficiente na detecção de heterozigotos para a D21OH, 
com valores de corte entre (60-70 ng/dL). Foram estabelecidos também por Fiet et al 
(31)
 
valores diagnósticos para a forma NC de 21DF após-ACTH: 400 ng/dL. No entanto, 
estudos mais recentes conjugando a genética molecular para confirmação das diferentes 
populações, evidenciaram que muitos indivíduos aparentemente normais (sem mutação do 
gene CYP21) apresentavam níveis acima de 60-70 ng/dL, atenuando a sensibilidade do 
21DF previamente descrita 
(32)
. Entretanto, valores falso-positivos poderiam também ser 
devidos à imprecisão metodológica dos radioimunoensaios empregados (apesar dos 
procedimentos de prévios de extração) 
(33)
.  
Apesar de pouco empregados no diagnóstico da D21OH, a caracterização 
dos esteróides distais ao bloqueio enzimático, como o 11-deoxicortisol (S) e o cortisol (F), 
produtos da via 17-hidroxilada, e a deoxicorticosterona (DOC) e a corticosterona (B), 
produtos da via não 17-hidroxilada da zona fasciculada (ZF), poderiam ser 
complementares na caracterização das diferentes formas de D21OH 
(34,35)
. Mais 
especificamente, as relações envolvendo precursores e produtos da 21OH, como a 17OHP 
e o 21DF sobre S, DOC e B, poderiam ser importantes instrumentos diagnósticos para a 
detecção de heterozigotos. Algumas dessas relações, como a 17OHP/DOC e a 
17OHP/18OHDOC, foram estudadas anteriormente 
(36,37)
, sem, entretanto, a devida 
comprovação molecular das populações.  
Na última década, a espectrometria de massa em tandem precedida da 
cromatografia líquida (LC-MS/MS), tornou-se o método ideal para a quantificação de 
esteróides 
(38)
, além de sua vantagem em dosar vários esteróides simultaneamente em 
pequeno intervalo de tempo (minutos). Enquanto a cromatografia prévia possibilita a 
separação de esteróides de peso molecular semelhante (isômeros), o MS/MS utiliza a 
relação massa/carga elétrica gerada pela fragmentação dos diversos esteróides, 
permitindo sua caracterização com excelente especificidade 
(39)
. 
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Objetivos 
Com base no emprego da metodologia de LC-MS/MS para a dosagem de 
esteróides séricos, e na caracterização precisa dos grupos estudados pelo emprego da 
genotipagem da CYP21A2, o presente estudo se propos a: 
(a) examinar a possível vantagem da dosagem sérica basal e após 
estímulo com ACTH do 21DF em relação à 17OHP na 
diferenciação entre heterozigotos para a D21OH e indivíduos 
normais e estabelecer valores de corte (cutoffs) desses esteróides nessas 
populações; 
(b) avaliar o comportamento dos esteróides distais ao bloqueio da 21-
hidroxilase (S, DOC e B), tanto individualmente como através da 
relação com seus precursores - 17OHP e 21DF -, nos diferentes 
subtipos de D21OH (pacientes com a forma clássica e não clássica), 
heterozigotos e indivíduos normais; 
(c) realizar o estudo de frequência das mutações detectadas nos pacientes 
com a D21OH, e correlacionar os níveis de 21DF e 17OHP nos 
diversos grupos genotípicos de pacientes e de heterozigotos para a 
D21OH. 
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Abstract 
Background: Congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency (21OHD) is 
an autosomal recessive disorder with a high prevalence of asymptomatic heterozygote carriers in 
the general population, making case detection desirable by routine methodology. Carriers for 
classic and nonclassic (NC) forms have basal and ACTH-stimulated values of 17-
hydroxyprogesterone (17OHP) that fail to discriminate them from the general population. 21-
Deoxycortisol (21DF), an 11-hydroxylated derivative of 17OHP, could be an alternative approach 
to identify carriers for 21OHD. Objective and Methods: To determine the discriminating value of 
basal and ACTH-stimulated serum levels of 21DF in comparison to 17OHP in a population of 
genotypically-confirmed carriers for 21OHD (n=62), as well as in affected patients (31 classic; 12 
NC) and in 26 genotypically normal control subjects (CS), using tandem mass spectrometry after 
HPLC separation (LC-MS/MS). Results: Basal 21DF levels were not different between carriers 
and CS, but stimulated values were significantly increased in the former and virtually non-
responsive in CS. Only 17.7 % of the ACTH-stimulated 21DF levels overlapped with CS, as 
compared to 46.8 % for 17OHP. For 100 % specificity, the sensitivities achieved for ACTH-
stimulated 21DF and 17OHP were 82.3 % and 53.2 %, using cutoffs of 40 ng/dL and 298 ng/dL, 
respectively. A positive and highly significant correlation (r= 0.785; p<0.0001) was observed 
between 21DF and 17OHP. Conclusion: This study confirms the superiority of ACTH-stimulated 
21DF, as compared to 17OHP, measured by LC-MS/MS, in identifying carriers for 21OHD. Serum 
21DF could be useful in genetic counseling to screen carriers among relatives in families with 
affected subjects, supporting molecular results. 
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Introduction 
21-Hydroxylase deficiency (21OHD) is an autosomal recessive disorder that results in 
the most frequent form of congenital adrenal hyperplasia (CAH). According to the mutation 
affecting the CYP21A2 gene, 21OHD will manifest in two clinical forms: classic and nonclassic 
(NC). The former, which is further subdivided into two types – with or without sodium loss (or 
simple virilizing) – manifests early in life, whereas the latter is either asymptomatic or diagnosed 
around puberty, especially in girls 
(1,2)
. 
The prevalence of asymptomatic carriers for the disease in the general population has 
been estimated from 1:50 (classic form) to as high as 1:16 (NC form) 
(3)
; in Ashkenazi Jews the 
carrier frequency is even higher, at 1:3 
(4)
. 
Elevated plasma 17-hydroxyprogesterone (17OHP) is the hallmark of 21OHD: 
whereas basal levels are extremely high in classic 21OHD, NC patients may have normal to 
slightly elevated basal levels, but a marked increase following ACTH stimulation 
(5-7)
.  
Carriers for both classic and NC forms have basal and ACTH-stimulated values of 17OHP that fail 
to discriminate them from the general population, although the response to ACTH tends to be 
higher in carriers 
(8)
. Thus, molecular analysis of the CYP21A2 gene is critical to distinguish 
between the several forms of 21OHD, including the carrier status; however, this methodology is 
time consuming and not widely available. 21-Deoxycortisol (21DF) is an 11-hydroxylated 
derivative of 17OHP produced solely in the adrenal cortex. Because this pathway is negligible in 
normal subjects, serum 21DF seems useful as an alternative approach to screen carriers for 
21OHD 
(9)
. Previous studies suggested that ACTH-stimulated serum levels of 21DF are more 
sensitive than 17OHP in identifying 21OHD carriers among the general population, using 
immunoassay methods 
(10,11)
.  
In the present study, we employed tandem mass spectrometry after HPLC separation (LC-
MS/MS) to determine the discriminatory value of basal and ACTH-stimulated serum levels of 21DF in 
comparison to 17OHP in a cohort of genotypically-confirmed heterozygote carriers for classic and NC 
21OHD, as well as in affected patients and in genotypically normal control subjects (CS).  
 
Subjects and Methods 
Subjects 
The study encompassed 132 individuals: (a) 61 obligatory carriers (32F/29M; 23-62y; 
median: 39y) who were parents of affected patients with 21OHD followed in our institution (53 
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had children with the classic and 8 with the NC form); (b) 41 affected patients (probands) with 
21OHD: 31 with the classic (21F/10M; 1-23y; median: 11y) and 10 with the NC forms (10F; 4-
42y; median: 17.5y); and (c) 30 normal control subjects (CS; 19F/11M; 23-62y; median: 37y). 
All carriers and CS denied the use of steroids or other medications that could 
potentially interfere with the study protocol, except for three female carriers who were on oral 
contraceptives. All adult women were pre-menopausal, except for three female carriers who were 
into menopause for at least 3y with no replacement therapy. Clinical hyperandrogenism was an 
exclusion criterion for normal control women. All 21OHD patients who were followed on regular 
replacement therapy had their medications withheld for 48h before the study. 
The protocol was previously approved by the Ethics Committee of all institutions 
involved in the study and informed written consent was obtained from all participants and/or their 
responsible. 
 
Methods  
All subjects were submitted to an ACTH stimulation test (Synacthen
®
, Novartis, 250 
μg IV bolus) performed in the morning, after overnight fasting, with blood samples drawn at 0 
(between 0800 h and 0900 h) and 60 min after injection, except for nine 21OHD classic patients 
who had only baseline blood drawn at the time of diagnosis. An extra sample was also drawn at 
time 0 for molecular studies. All pre-menopausal women were studied in the early follicular phase 
of the menstrual cycle. Serum was separated within 2 h from collection and kept frozen at -20 °C 
until assayed.  
 
Hormonal Assays 
Serum 21DF, 17OHP, and cortisol were simultaneously determined in each sample by 
LC-MS/MS after on-line extraction, according to a recently described method 
(12)
. The intra- and 
inter-assay coefficients of variation for 21DF, 17OHP, and cortisol were 10 % and 13.3%, 7.5% 
and 7.9%, and 3.0% and 8.7%, respectively. Quantification limits were respectively: 24 ng/dL, 
15 ng/dL and 0.45 µg/dL. To convert metric (ng/dL) to SI units (nmol/L) multiply 21DF by 0.0289 
and 17OHP by 0.0303; to convert µg/dL to nmol/L multiply cortisol by 27.6.  
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Molecular Analysis 
DNA samples were extracted from peripheral blood leukocytes by standard 
procedures. DNA of the parents were screened for the point mutations found in the index case by 
allelic specific PCR 
(13,14)
. Complete CYP21A2 gene sequencing 
(14)
 was performed: (a) in all CS; 
(b) whenever stimulated 17OHP was higher than 1,000 ng/dL 
(15)
, and/or (c) if no mutations were 
detected in the carriers. 
 
Subjects Relocation 
After genotyping, and regardless of hormonal results, several relocations were 
mandatory among the participants: (a) two former male carriers (classic form) were found to be 
affected NC 21OHD patients; (b) four of the former CS were found to be carriers for 21OHD: two 
for the NC and one for the classic form; the fourth presents a new intronic substitution that is 
presently under investigation; thus, this patient was excluded awaiting further definition. All others 
were properly relocated. 
After regrouping, the final numbers used for statistical analysis were: (a) 62 carriers, 
52 of whom with the classic (27F/25M; 23-62y) and 10 with the NC form (7F/3M; 29-45y), (2) 31 
classic (21F/10M; 1-23y) and 12 NC patients (10F/2M; 9-58y), and (3) 26 CS (15F/11M; 23-65y). 
 
Statistical Analysis 
Statistical Package for the Social Sciences for Windows, Version 13.0 (SPSS Inc. 
Chicago, IL, USA) was used for calculations. Receiver operator characteristics (ROC) curves were 
used to define the cutoff points for ACTH-stimulated serum 21DF and 17OHP in the 
genotypically-confirmed populations of 21OHD carriers and CS. The one-way non-parametric 
ANOVA Mann-Whitney U test was used for comparisons between groups. For statistical purposes, 
all values below the quantification limit for the particular steroid were arbitrarily considered equal 
to the quantification level divided by the square root of 2 (therefore defining an average number for 
all undetectable values). 
All results are presented in the text and tables as the mean ± SD and the median (and 
range) for all three steroids in the several groups. All statistical differences <0.05 (5%) were 
considered significant.  
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Results 
Any comparison with the 21OHD patients would have to consider that their 
replacement therapy was withheld for only 48 h (for ethical reasons), a period not necessarily 
sufficient to permit a full reemergence of the pre-treatment steroid profile. This consideration is 
particularly true when analyzing the overlap of serum 21DF values that occurred between 21OHD 
patients and carriers in this study. 
Because there were no statistical differences between classic and NC carriers for all 
three steroids (table 1), both groups were subsequently combined for statistical purposes and named 
simply 21OHD carriers. 
 
21DF (table 1; figure 1) 
Although stimulated 21DF values were similarly elevated in classic and NC 21OHD 
patients, basal levels were significantly higher in the former (p<0.0001). Basal 21DF levels were 
higher in carriers than CS (p<0.04), and stimulated values were significantly increased in the 
former (p<0.0001) and virtually non-responsive in CS. While basal 21DF was undetectable in all 
but 9 carriers (14.5 %) and all CS, post-ACTH values remained undetectable in only 6 carriers (9.7 
%), but in all CS, except two in whom values were barely above detection (29.5 and 39 ng/dL) 
(figure 1). 
Only 11 out of the 62 carriers (17.7%) overlapped with CS regarding stimulated 
21DF. Thus, 82.3% of the carriers had 21DF above 39 ng/dL, the highest normal post-ACTH 
value. 
In the conditions of the study (short term glucocorticoid withdrawal), six out of the 
forty-three 21OHD patients (5 classic and 1 NC), still had ACTH-stimulated 21DF values that 
overlapped with carriers. Nevertheless, the lowest basal and post-ACTH 21DF levels observed in 
the six untreated NC patients (164 and 1,319 ng/dL) were above the upper limits observed in 
carriers (76 and 412 ng/dL, respectively). 
 
17OHP (table 1, figure 1) 
Classic 21OHD patients had both basal and stimulated 17OHP levels that were 
significantly increased as compared to NC patients (p<0.0001). Although basal 17OHP levels were 
not different between carriers and CS, stimulated levels were significantly higher in the former 
(p<0.0001); however, individual post-ACTH 17OHP values disclosed an important overlap with 
ARTIGO 1 
21 
CS (29 out of 62 carriers; 46.8 %) (figure 1). Thus, only 53.2 % of the carriers had values above the 
upper normal limit (298 ng/dL). 
 
Correlation between 21DF and 17OHP (figure 2) 
A positive and highly significant correlation (r= 0.7854; p<0.0001) was observed 
between all 21DF and 17OHP pairs of values (basal and post-ACTH; n= 201) obtained from all 
carriers and classic and NC 21OHD patients.  
 
Cortisol (table 1) 
Classic 21OHD patients had low basal and ACTH-unresponsive cortisol levels, 
whereas NC patients had normal basal but impaired responses. 21OHD carriers had both basal and 
post-ACTH cortisol values that were virtually identical to CS. 
 
ROC Curve 
Basal levels of both 21DF and 17OHP were not accurate enough to separate 21OHD 
carriers from CS, but when ACTH-stimulated values were used, the area-under-the-curve (AUC) 
for 21DF was significantly larger than that for 17OHP (0.944 and 0.858, respectively; p<0.0001). 
Also, the cutoff point defined for ACTH-stimulated 21DF – 32.7 ng/dL -, provided 87.1 % 
sensitivity and 96.2 % specificity for distinguishing carriers from CS, whereas that for 17OHP – 
200 ng/dL -, conferred only 82.3 % sensitivity and 84.6 % specificity. For 100 % specificity, the 
sensitivities achieved for ACTH-stimulated 21DF and 17OHP were 82.3 % (40 ng/dL) and 53.2 % 
(298 ng/dL), respectively. 
 
Discussion 
In its classic form, 21OHD is a serious and even fatal disease. Because the prevalence 
of heterozygote carriers for 21OHD in the general population is high, and obviously higher among 
populations at risk (e.g.: relatives in families with an affected patient) 
(3)
, their screening and case 
detection using routine methodology is greatly desirable. In the present study we demonstrate the 
advantage of ACTH-stimulated serum levels of 21DF in comparison to 17OHP (both determined 
by LC-MS/MS) in distinguishing genotypically-confirmed carriers for 21OHD from normal control 
individuals (“wild-types” for CYP21A2 gene mutations). 
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Serum/plasma 17OHP has been generally considered the best biochemical marker for 
the diagnosis of 21OHD. However, it is also known that ACTH-stimulated 17OHP fails to identify 
the carrier state in 20 % to 71 % of the cases 
(16-19)
. Considerable overlap is also observed between 
carriers and normal controls using the incremental rate of 17OHP (in ng/dL/min) following ACTH 
infusion 
(20)
. The same difficulty was shown when ACTH stimulation was preceded by adrenal 
suppression with overnight dexamethasone 
(21)
. Somewhat better results were reported with the use 
of substrate/product steroid ratios after ACTH stimulation: 17OHP:18-hydroxy-
deoxycorticosterone (18OHDOC) ratio disclosed 94 % separation 
(22)
, whereas 17OHP:DOC ratio 
was reported in one study to result in 100 % separation 
(23)
. 
Moreover, the methodology for steroid quantification has advanced from classic 
radioimmunoassay 
(24,25)
 to up-to-date highly specific tandem mass spectrometry preceded by liquid 
or gas chromatography 
(26,27)
, in special for steroids whose determinations are not widely available, 
as 21DF 
(28)
. Because 21DF is an 11 -hydroxy-derivative of 17OHP and its production is limited to 
the adrenal cortex, its serum levels are significantly and concurrently elevated in the affected 
patient with 21OHD, whereas its production is virtually nil in normal subjects 
(29)
. Thus, 21DF 
response to ACTH stimulation might be a distinctive feature of the carrier state, as has been 
proposed in previous studies 
(10,18,30)
. The strong positive correlation observed between 21DF and 
17OHP in our carrier population, as well as in 21OHD classic and NC patients, indicates the 
functionality of this otherwise inactive pathway. 
Using a cutoff point of 40 ng/dL for ACTH-stimulated 21DF we could discriminate 
carriers from CS with greater accuracy than using 298 ng/dL for ACTH-stimulated 17OHP (82.3% 
vs 53.2% sensitivity, for 100% specificity). Also, different from Tardy et al 
(11)
, who detected 
“some normal genotyped subjects with post-ACTH 21DF higher than 50 ng/dL”, and Bidet et 
al 
(31), who found 3 out of 37 (8.1%) “unaffected subjects” with values higher than 53 ng/dL, none 
of our genotypically-confirmed CS had ACTH-stimulated 21DF values above 40 ng/dL. Thus, the 
LC-MS/MS methodology employed in the present study to measure 21DF seems to warrant enough 
consistency to recommend its use towards the detection of carriers for 21OHD.  
In our series, one female carrier had exaggerated 21DF and cortisol responses to 
ACTH (412 ng/dL and 37.9 g/dL, respectively, - the highest values among carriers), in face of 
moderately elevated 17OHP (960 ng/dL). Subsequently, she admitted the use of a contraceptive pill 
for 21 days before the study. Similar but less apparent values were observed for the other two 
carriers who were also on birth control pills (21DF: 187 and 171 ng/dL; cortisol: 32.7 and 23.1 
g/dL). Pregnancy and use of estrogen/progesterone products are known to be associated with 
elevated cortisol and 21DF levels due to the increased concentration of cortisol binding globulin 
(18). Thus, caution must be exerted whenever ACTH-stimulated cortisol levels are above 30 
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g/dL, since they could be related to falsely elevated 21DF and 17OHP (and false-positive case 
detection of carriers) 
(7)
. On the other hand, six carriers (4 classic and 2 NC) had unresponsive 
21DF after ACTH (< 17 ng/dL), similar to most CS. Although only one admitted the use of 
corticosteroid medications, we could not exclude the unintentional use of corticosteroid-containing 
creams and nasal sprays that could impair 21DF response to ACTH. In fact, several affected 
patients in our study had low ACTH-stimulated 21DF levels that overlapped with carriers, different 
from their respective 17OHP levels that clearly segregate. In view of the short corticosteroid 
withdrawal period in these patients, reemergence of 17OHP seems to precede that of 21DF, 
suggesting that the latter is more sensitive to ACTH suppression. 
These data validate the superiority of ACTH-stimulated serum 21DF, as compared to 
17OHP - both measured by LC-MS/MS -, in identifying carriers for 21OHD. Even though 
molecular analysis is the “gold standard” in diagnosing subtypes of 21OHD, serum 21DF seems to 
be a useful tool in genetic counseling to screen for carriers among relatives in families with 
affected subjects, supporting molecular results. A further gain in assay sensitivity for 21DF will 
hopefully permit a better separation in the near future. 
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Table 1: Mean (±SD) and median [range] of basal and post-ACTH cortisol, 17OH-progesterone 
(17OHP), and 21-deoxycortisol (21DF), in patients with 21OHD (22 classic; 12 NC), carriers (52 
classic; 10 NC), and 26 control subjects. (despite being presented in separate, classic and NC 
carriers were combined for statistical analysis). 
*
p<0.0001 vs NC patients, carriers, and CS; 
&
p<0.0001 vs carriers and CS; 
†
p<0.0001 vs carriers 
and CS; £p<0.04 vs CS; ££ p<0.0001 vs CS. 
 
 
 21DF (ng/dL) 17OHP (ng/dL) Cortisol (g/dL) 
 Basal Post-ACTH Basal Post-ACTH Basal Post-ACTH 
Classic 
21OHD 
Patients 
1,238 1,692* 
463 
[154-7,079] 
1,438 1,656
&
 
748 
[143-6,326] 
12,841 8,855* 
11,346 
[816-34,911] 
15,329 10,108*
 
14,651 
[1,185-40,090] 
 1.1 1.2* 
0.6
 
[0.2-4.4] 
 1.1 1.1* 
0.7 
[0.2-3.3] 
Nonclassic 
21OHD  
patients 
300 395† 
161 
[47-1,423] 
1,577 1,094† 
1,260 
[302-3,619] 
2,113 3,535† 
1,068 
[574-13,293] 
7,095 3,339† 
6,649 
[3,008-13,256] 
11.3 5.3 
 
9.7 
[6.1-25.0] 
16.5 6.4† 
14.8 
[6.4-32.5] 
Classic  
21OHD 
Carriers 
19.9 10.3 
17.0 
[17.0-76.0] 
98.5 73.4 
81.5 
[17.0-412.3] 
88 75 
71 
[20- 445] 
419 308 
314 
[60-1,347] 
10.5 4.3 
9.9 
[3.0-22.8] 
24.3 5.4 
23.8 
[13.5-37.9] 
Nonclassic 
21OHD 
Carriers 
30.5 18.1
£
 
17.0 
[17.0-60.0] 
109.3 87.7
££
 
89.5 
[17.0-295.9] 
79.2 75.9 
45.2 
[23-256] 
487 507
££
 
265 
[143-1,704] 
10.4 5.8 
7.7 
[5.9-24.0] 
24.4 3.6 
25.3 
[17.1-29.0] 
Normal 
control 
subjects 
17.0 0.1 
17.0 
[17.0-17.0] 
18.3 4.9 
17.0 
[17.0-39.0] 
60.6 40.6 
54.8 
[10.6-175] 
162.9 57.2 
162.7 
[63.2-296.4] 
10.3 3.6 
10.0 
[5.4-17.4] 
24.1 4.3 
24.0 
[16.3-31.7] 
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Figure 1: Individual ACTH-stimulated serum 21DF and 17OHP levels in 21OHD subtypes: classic 
and nonclassic (NC) patients, combined classic and NC carriers and control subjects. 
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Figure 2: Correlation between serum 21DF and 17OHP (basal and ACTH-stimulated levels) in 
21OHD patients and carriers.  
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Abstract 
Introduction: In 21-hydroxylase deficiency (21OHD) there is a good correlation between 
genotype and basal 17-hydroxyprogesterone (17OHP) levels in the classic, and also with post-
ACTH 17OHP levels in the nonclassic (NC) form, but not in carriers. 21-Deoxycortisol (21DF) is a 
good biochemical marker of 21OHD, in special to identify the “carriers”, but there are no studies 
correlating 21DF levels with genotypes. Objective: Compare 21DF and 17OHP levels - 
determined by LC-MS/MS -, with genotype in 29 21OHD patients and in 62 heterozygote carriers. 
CYP21A2 from all subjects were sequenced and the genotypes classified according to residual 
enzymatic activity: Group A (mutations abolishing the enzymatic activity), B (3-7% of residual 
activity) and C (20%-50% residual activity). Results: Mutations were identified in 85/88 (96.5%) 
of alleles from the patients; the 3 unidentified alleles were from NC patients. Basal but not post-
ACTH 21DF was significantly higher in the A group compared to the C group, whereas both basal 
and post-ACTH 17OHP were significantly higher in the former group. In carriers, there were no 
differences in basal and post-ACTH 17OHP and 21DF levels between A, B, and C groups. Post-
ACTH 21DF and 17OHP levels higher than 300ng/dL and 1,700/dL, respectively, could 
discriminate NC patients from carriers. Conclusion: Basal 21DF levels differentiated A to C 
genotypes in the patient groups, demonstrating its utility for diagnostic purposes, such as in boys in 
the neonatal period. Additionally, difficulties in differentiating NC form from carriers with 17OHP 
profiling could be determined with the use of 21DF.  
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Introduction 
Congenital adrenal hyperplasia owed to 21-hydroxylase deficiency (21OHD) is one of 
the commonest autosomal recessive disorder in humans 
(1,2)
. The clinical spectrum of the disease 
encompasses classic and nonclassic (NC) forms reflecting the residual 21-hydroxylase activity, 
resulting from the wide range of CYP21A2 gene mutations. In the most severe salt wasting (SW) 
form, the enzymatic activity is null (its genotype is termed type A), whereas in the simple virilizing 
form (SV), less than 5% of residual adrenal 21-hydroxylation appears sufficient to prevent salt loss, 
but not virilization manifestations in the neonatal and/or post-natal periods (type B genotype). In 
the milder NC form, in which remaining enzymatic activity varies from 20% to 50% (type C 
genotype), patients can be asymptomatic or manifest hyperandrogenic signs during childhood or 
early adult life 
(3)
.  
Until recently, the human gene mutation database (www.hgmd.cf.ac.uk) depicted 
more than 150 different CYP21A2 gene mutations, two-thirds of which represented by point 
mutations. Among the ethnic heterogeneous Brazilian population, as it occurs in other populations, 
most of the affected alleles carry mutations derived from gene conversion events involving the 
active (CYP21A2 ) and its highly homologous  pseudogene (CYP21A1P), and a high frequency of 
alleles with multiple mutations are observed 
(4-9)
. 
Because most patients are compound heterozygotes, their phenotypes result from the 
less impaired allele 
(1-3)
. A good correlation between genotype and 17-hydroxyprogesterone 
(17OHP) levels is observed in classic and NC 21OHD 
(10,11)
, but not in carriers for the disease 
(12-15)
.  
21-deoxycortisol (21DF) is an additional biochemical marker of 21OHD that has been 
shown to be superior to 17OHP in: (a) the follow-up of adolescent and adult patients with 21OHD 
during treatment 
(16)
 and, (b) identifying the “heterozygote carrier state” (17,18). However, there are 
no studies correlating 21OHD genotypes and 21DF 
(19)
. Considering, that CYP21A2 molecular 
analysis is not an easy and widely available methodology, the 21DF measurements could be a 
useful tool in identifying the different phenotypes of 21-hydroxylase deficiency, which present 
important implications in the treatment decisions and genetic counseling.   
In the present study, we analyzed the basal and pos-ACTH 21DF and 17OHP levels, 
both determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS), among the 
different 21OHD phenotypes for diagnostic purposes. In addition, we evaluated whether the 
different genotype severities, in patients and carriers, could be predicted by the basal and pos-
ACTH 21DF and 17OHP levels. 
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Subjects and Methods 
The study encompassed a cohort of 45 Brazilian patients with classic and NC 21OHD 
and 62 heterozygote carriers for the disease.  The patients were: 43 unrelated index cases, being 33 
with the classic (25 SW; 18F/7M, and 8 SV; 6F/2M) and 10 with the NC form (10F), and two 
parents (2M), who were identified as affected by NC form during genotyping. The carriers were 
31F/28M obligatory heterozygotes, parents from index cases and another three (3F) detected 
among the general population by entire CYP21A2 sequencing. All but, three female carriers 
admitted the use of oral contraceptives. 21OHD patients who were followed on regular replacement 
therapy had their medications withheld for 48h before the study 
(16)
. 
Diagnosis of 21OHD was confirmed in the newborn period or early infancy in all 
classic patients by hormonal profiling (basal 17OHP > 5,000 ng/dL). The NC female patients were 
diagnosed in the adolescence or early adult life during investigation for hirsutism and/or menstrual 
irregularities, except for three who presented with precocious pubarche and advanced bone age; all 
had ACTH-stimulated 17OHP above 3,000 ng/dL. The two NC male patients mentioned above 
were asymptomatic and presented normal fertility. 
Analysis of frequency of the CYP21A2 gene mutations was carried out exclusively in 
the 43 index cases, plus two unrelated alleles from the affected parents, summing up 88 nonrelated 
alleles. We also determined the frequency of mutations in the 62 carriers. 
All subjects enrolled in the study gave their informed written consent after being told 
of the purposes of the present protocol that have been previously approved by the Ethic 
Committees in Human Research of both institutions.  
 
Molecular Analysis 
DNA samples were extracted from peripheral blood leukocytes by standard 
procedures. Patients were screened by allele-specific PCR for the 15 most frequent point 
mutations 
(6,14)
. If no mutations were found, the entire gene was sequenced. The mutations found in 
the index cases were segregated in DNA samples from all obligatory heterozygotes, Complete 
CYP21A2 gene sequencing, including the promoter region, was performed whenever stimulated 
17OHP was higher than 1,000ng/dL in the obligatory heterozygotes 
(20)
.  
When a large rearrangement was suspected, as suggested by point mutations in 
homozygous state, a MLPA-multiplex ligation-dependent probe amplification (SALSA MLPA kit 
P050B CAH, MCR-Holland, Amsterdam, The Netherlands) was employed to differentiate 
CYP21A2 deletions from large gene conversions 
(21)
. The SALSA MLPA kit contains 5 specific 
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probes for the active 21-hydroxylase gene, 3 for the pseudogene, one for the C4B and one for the 
C4A genes. 
 
Genotype Categories 
CYP21A2 genotypes were grouped according to the predicted impairment of 
enzymatic activity observed in in vitro studies 
(3)
: type A genotype (carry mutations resulting in  
total or near total impairment of 21OH activity), this group comprised patients homozygotes or 
compound heterozygotes for mutations I2 splice, Q318X, CYP21A2 deletion and large gene 
conversion, etc); type B genotype (resulting in severe impairment or less than 7%  of residual  
activity), comprised patients homozygotes for the I172N mutation, or compound heterozygosis 
with any type A mutation; and type C genotype (moderate impairment or 20%-50% of residual 
activity), comprised patients homozygotes for V281L, P30L, P453S, R339H, and V304M, or 
compound heterozygosis with any group A or B mutations. 
Since carriers have one normal or non-affected allele that presumably expresses full 
enzymatic activity, the frequency analysis and genotype/phenotype correlations in this group were 
done only for academic purposes, employing the single mutated allele and the same classification. 
 
Hormonal Assays 
Thirty of the 45 patients (12 SW, 6 SV, and all 12 NC - including the two 
asymptomatic fathers) and all 62 carriers were submitted to an ACTH stimulation test (Synacthen
®
, 
Novartis, 250μg IV bolus) performed in the morning, after overnight fasting and 30’ recumbence; 
blood samples were drawn at 0 (around 08:30h) and 60 min after injection. All premenopausal 
women were studied in the early follicular phase of the menstrual cycle.  Serum 21DF and 17OHP 
were simultaneously determined in each sample by LC-MS/MS, according to a previously 
described method 
(22)
. The intra- and inter-assay coefficients of variations for 21DF were 10% and 
13.3%, and for 17OHP, 7.5% and 7.9%. To convert metric (ng/dL) to SI units (nmol/L) multiply 
21DF by 0.0289 and 17OHP by 0.0303. 
 
Statistical Analysis 
The one-way non-parametric test of Kruskal-Wallis was used for comparisons 
between groups. For statistical purposes, all values below the quantification limit for the particular 
steroid were arbitrarily considered equal to the quantification level divided by the square root of 2 
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(therefore defining an average number for all undetectable values). A P value <0.05 was considered 
statistically significant.  
 
Results 
21OHD Patients 
A total of 17 different mutations were identified in 85 of the 88 (96.6%) alleles 
investigated, 88.2% of which being point mutations. A single mutation was present in 77 of the 85 
(90.6%) identified alleles, whereas two (7/85; 8.3%) and three (1/85; 1.1 %) mutations per allele 
were documented in the remaining eight. I2 splice was the most frequently observed mutation 
(23.5%), followed by V281L (22.3%), R356W (14%), and I172N (11.8%), accounting for 71.6% 
of all mutations. In the NC form, V281L was present in 16 out of the 22 alleles (72.7%), whereas in 
SV, I172N was present in 62.5% and in SW form; I2 splice was present in 36% of the alleles 
(Table 1). 
Twenty patients were homozygotes and 25 were compound heterozygotes (Table 2). 
One SV (type B) female patient disclosed a rare mutation - V304M (23) - in cis with the I172N 
mutation, confirmed by segregation analysis in the parent DNA samples. 
In two NC female patients, despite they presented serum steroid levels compatible 
with the NC form diagnosis (basal 17OHP: 1,431 and 1,223 ng/dL, post-ACTH 17OHP: 8,839 and 
8,056ng/dL, and post-ACTH 21DF: 842 and 1,319ng/dL, respectively), mutations were identified 
in only one allele (V281L) from the first patient and in none from the second one. The entire 
CYP21A2 sequencing identified a new substitution A>G in the splice acceptor site of intron 5 in the 
former patient, disclosing the genotype V281L/IVS 5 – 2 A>G. However, this patient was excluded 
from data analysis until functional studies will be concluded. In the other patient, no mutations 
were identified despite exhaustive sequencing. Both patients are identified with question marks in 
Table 2. 
We also included as NC patients two asymptomatic parents who had elevated 17OHP 
(basal: 856 and 1,087ng/dL, post-ACTH: 6,566 and 12,492ng/dL) and 21DF levels (basal: 203 and 
233ng/dL, post-ACTH: 1,885 and 2,964ng/dL). Their molecular analysis disclosed the genotypes 
V281L/I2 splice and V281L/R356W, which belong to group C (Table 2). 
When 21OHD patients were separated according to the genotype category, basal 21DF 
and 17OHP levels were significantly higher in group A as compared to group C. However, post-
ACTH levels were significantly higher in group A vs C only for 17OHP (Table 3). There were no 
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statistical differences between groups A vs B, or B vs C, for both basal and post-ACTH 21DF and 
17OHP levels. 
Among the 10 completely genotyped NC patients six were homozygous for the V281L 
mutation (C/C), whereas four were compound heterozygous for mutations from group A (A/C). 
The latter group, harboring a severe (A) mutation had higher post-ACTH 17OHP levels than the 
former, whereas no differences were observed for 21DF levels.  
 
21OHD Carriers 
The most frequent mutations detected in the heterozygote carriers were: I2 splice, 
V281L, R356W, large gene conversion/CYP21A2 deletion, and Q318X, accounting for 72.7% of 
all mutations (Table 1). Seven carriers (11.3%) had two or three point mutations in the same allele. 
Although asymptomatic, carriers were also grouped according to the mutated allele in: group A 
(n=46; 74.2%), group B (n=6; 9.7%) and group C genotypes (n=10; 16.1%).  
Since basal and ACTH-stimulated 21DF and 17OHP levels were almost identical in 
genotype groups A, B, and C, their values were combined in Table 3. 
Five genotypically confirmed carriers had stimulated 17OHP values between 1,000-
1,500ng/dL. Three of them, carrying mutations from group A, had high ACTH-stimulated 17OHP 
levels (1,347; 1,289; and 1,256 ng/dL), with somewhat different stimulated 21DF (91; 267; 
217ng/dL, respectively). The two remaining carriers had similar post-ACTH 17OHP and 21DF 
values (post-ACTH 17OHP and 21DF of 1,103 and 1,044ng/dL, and 182 and 184ng/dL, 
respectively) despite they carried mutations from groups B and C, respectively.  
Another asymptomatic female carrier had the highest post-ACTH 17OHP and 21DF 
levels at 1,704 and 296ng/dL, respectively. However, she was confirmed as a group C carrier since 
only one V281L mutation was detected after exhausting sequencing.  
 
Discussion 
Molecular analysis is the gold standard for the diagnosis and classification of 21OHD 
phenotypes, including the carrier state. In this paper, we report the frequencies of CYP21A2 gene 
mutations in a cohort of Brazilian patients and carriers for the 21OHD form of CAH. The four most 
prevalent CYP21A2 gene mutations from the 17 found in our study (I2 splice, R356W, V281L, and 
I172N) accounted for more than two-thirds of all detected mutations; I2 splice was the most 
frequent one (23.3%). Even in the presence of the ample miscegenation of the Brazilian population, 
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the frequency of CYP21A2 gene mutations in this series was similar to other worldwide screening 
studies 
(1, 24-29)
.  
At present, as also observed in this series, all mutated alleles could be identified in 
classic 21OHD applying entire CYP21A2 gene sequencing 
(29)
. However, in spite of the advances in 
molecular genotyping for 21OHD, up to 20% of the alleles from NC form remain  
unidentified 
(19,29-31)
. In our series, we were not able to identified mutations in 13% of the NC 
alleles. 
Earlier studies with classic 21OHD demonstrated that genotype correlates better with 
clinical (SW and SV) than hormonal parameters (17OHP, plasma renin), whereas in the NC form, 
these correlations are less evident 
(1,10,32,33)
. In our data, there was a fair correlation between 
genotype categories A, B, and C with basal and stimulated 17OHP. Because 21DF is a product of 
17OHP, its basal levels were also higher in group A than in group C patients. Surprisingly, 
stimulated 21DF levels were not significantly different among these groups; in fact, there was a 
trend towards higher values in group C than in group A and B patients. It may be possible that the 
short-term glucocorticoid washout (only two days) in classic patients was not sufficient for this 
susceptible steroid to recover from ACTH suppression. Additional studies in untreated subjects 
may be necessary to clarify this discrepancy. 
Regarding NC patients, post-ACTH levels of 17OHP were higher in A/C than in C/C 
compound mutations, as previously reported 
(10,11,19)
; however, this was not observed with 21DF 
levels.  
Even though the unaffected allele is able to code normal 21-hydroxylase activity in 
carriers, ACTH-stimulated 17OHP levels are known to be variably increased in these subjects, 
suggesting that the mutated allele may interfere with the normal response 
(12-15,33)
. In several studies 
with 21OHD carriers, ACTH-stimulated 17OHP levels correlated inversely with the severity of the 
single mutated allele, suggesting a dominant-negative effect of the V281L mutation in carriers with 
high 17OHP levels 
(12,15,34)
. However, we and others 
(13,14)
 were not able to confirm these findings 
with either 17OHP or 21DF.  
According to several authors, carriers may reach ACTH-stimulated 17OHP levels up 
to 1,500 ng/dL 
(1,31,32)
, or 1,700 ng/dL 
(10)
, different from a previous threshold value of 1,000 
ng/dL 
(35,36)
. Actually, five of our carriers had post-ACTH 17OHP levels between 1,044 and 1,347 
ng/dL and also had very high 21DF levels (183-267 ng/dL). In addition, another carrier had 
elevated post-ACTH levels of 17OHP and 21DF even higher: 1,704 and 296 ng/dL, respectively; 
however, after repeated gene sequencing, a second mutation was not detected in this asymptomatic 
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female. On the other hand, the lowest ACTH-stimulated 17OHP level observed in our NC patients 
was 3.008 ng/dL. 
Despite the small sample of NC patients, and to the extent of the limitations imposed 
by the possible use of interfering medications (oral contraceptives, glucocorticoids) , the lowest 
ACTH-stimulated 21DF level in a genotypically confirmed NC patient in our series was 302 ng/dL, 
just above the highest stimulated 21DF level documented in carriers (296 ng/dL). Thus, in addition 
to the present upper limit for ACTH-stimulated 17OHP proposed by several authors 
(1,10,32)
 to 
separate carriers from NC 21OHD patients (1,500-1,700 ng/dL), we suggest a cutoff level of      
300 ng/dL for post-ACTH 21DF, lower than that of 400 ng/dL recommended by Fiet et al 
(16,37)
, in 
order to increase sensitivity. 
On the other hand, molecular studies may not be absolutely conclusive. For example, 
two of our alleged NC patients (noted with question marks in Table 2) disclosed post-ACTH values 
of 17OHP and 21DF well into the NC range 
(1,10,32,35)
, but could not be genotypically characterized 
as affected NC, despite repeated CYP21A2 gene sequencing, including the promoter region. Thus, 
in an attempt to identify new mutations in the so-far “unaffected” alleles in unidentified cases, strict 
genetic scrutiny is presently underway focusing on POR (P450oxido-reductase) gene variations 
that could modulate 21OHD phenotypes 
(29,38)
, and the search for an yet unrevealed factor(s) that 
could interfere with 17OHP and 21DF responses to ACTH.  
Therefore, even in the light of an appropriate molecular definition for 21OHD, 
establishment of distinct 17OHP and/or 21DF cutoff levels to separate NC 21OHD patients from 
carriers of the disease and those from normal controls (wild-types) may still be a matter of 
debate.In summary, genotype-phenotype correlation in patients with 21OHD was fair with serum 
17OHP, but only modest with 21DF levels. In carriers, post-ACTH 21DF and 17OHP did not 
correlate with the severity of the single mutated allele. Using LC-MS/MS methodology, post-
ACTH 21DF levels higher than 300ng/dL concurrently with post-ACTH 17OHP levels higher than 
1,700 ng/dL, were typical of NC 21OHD. Additionally, because routine CYP21A2 gene sequencing 
is not an easy and widely available methodology, difficulties in diagnosing 21ODH subtypes, 
particularly NC form and carriers with 17OHP profiling, could be better ascertained with the use of 
21DF.  
ARTIGO 2 
42 
References 
1. White PC, Speiser PW Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 
Endocr Rev 2000; 21: 245-91. 
2. White PC, Speiser PW  Congenital adrenal hyperplasia. N Engl J Med 2003: 776-88. 
3. Speiser PW, Dupont J, Zhu D, Serrsat J, Buegeleisen M, Tusie- Luna MT, Lesser M, New MI, 
White PC Disease expression and molecular genotype in congenital adrenal hyperplasia due to 
21- hydroxylase deficiency. J Clin Invest 1992; 90: 584-95.  
4. LC, Paulino, Araujo M, Guerra G Jr, Marini SH, De Mello MP  Mutational distribuition and 
CYP21/ C4 locus variability in Brasilian families with the classical form of the 21- hidroxylase 
deficiency. Acta Padiatr 1999; 88: 275-83. 
5. Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, Arnhold IJ, 
Mendonca BB  21-Hydroxylase deficiency in Brazil. Braz J Med Biol Res 2000; 33: 1211-16. 
6. Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, Arnhold IJ, 
Mendonca BB Molecular genotyping in Brazilian patients with classical and nonclassical forms 
of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2000; 83: 4416-19. 
7. Witchel SF, Smith R, Crivellaro CE, Della Manna T, Dichtchekenian V, Setian N, Damiani D 
CYP21 mutations in Brazilian patients with 21-hydroxylase deficiency. Hum Genet 2000; 106: 
414-19. 
8. Torres N, Mello, MP, Germano CM, Elias LL, Moreira AC, Castro M Phenotype and genotype 
correlation of microconversion from the CYP21A1P to the CYP21A2 gene in congenital adrenal 
hyperplasia. Braz J Med Biol Res 2003; 36: 1311-18. 
9. Campos VC, Pereira RM, Torres N, de Castro M, Aguiar-Oliveira MH High frequency of 
Q318X mutation in patients with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency in northeast Brazil. Arq Bras Endocrinol Metabol 2009; 53: 40-46. 
10. Bachega TA, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, Mendonca BB Influence 
of different genotypes on 17-hydroxyprogesterone levels in patients with non-classical 
congenital adrenal  hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 2000; 52, 
601-07. 
11. Weintrob N, Brautbar C , Pertzelan A, Josefsberg Z, Dickerman Z, Kauschansky A, Lilos P, 
Peled D, Philip M, Israel S Genotype- phenotype associations in non-classical steroid 21- 
hydroxylase deficiency. Eur J Endocrinol 2000; 143: 397-403. 
ARTIGO 2 
43 
12. Escobar-Morreale HF, San Millán JL, Smith RR, Sancho J, Witchel SF  The presence of the 
21- hydroxylase deficiency carrier status in hirsute women: phenotype- genotype correlations . 
Fertil Steril 1999; 72: 629-38. 
13. Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M Significantly 
higher adrenocorticotropin-stimulated cortisol and 17- hydroxyprogesterone levels in 337 
consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin 
Endocrinol Metab 2005; 90: 1347-53. 
14. Bachega TA, Brenlha EM, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, Mendonca 
BB .Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency 
carriers are not correlated to different CYP gene mutations. J Clin Endocrinol Metab 2002; 87: 
786-90.  
15. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y, Hyperandrogenism in carriers of 
CYP21 mutations: the role of genotype. Clin Endocrinol (Oxf), 2006; 64: 645-51. 
16. Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto LM, Verreschi ITN, 
Kater CE Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic 
congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients 
with 11 -hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. 
J Clin Endocrinol Metab 2006;  91: 2179-84. 
17. Fiet J, Gueux B, Gourmelen M, Kuttenn F, Vexiau P, Couillin P, Pham-Huu-Trung MT, 
Villette JM, Raux-Demay MC, Galons H, Julien R,Comparison of basal and 
adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as 
biological markers of late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1988; 66: 659-67 
18. Tardy V, Forest M, De Rougemont A, Morel Y Detection of heterozygotes for 21-hydroxylase 
deficiency: Validation of 21-deoxycortisol after ACTH test by sequencing of the entire CYP21 
gene. Horm Res 2005; 64 (S1), 41-42. 
19. Bidet M, Bellanné-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, Laborde K, Coussieu 
C, Morel Y, Vaury C, Golmard JL, Claustre A, Mornet E, Chakhtoura Z, Mowszowicz I, 
Bachelot A, Touraine P, Kuttenn F . Clinical and molecular characterization of a cohort of 161 
unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency and 330 family members. J Clin Endocrinol Metab 2009; 94: 1570-78.  
20. Billerbeck AE, Mendonca BB, Pinto EM, Madureira G, Arnhold IJ, Bachega TA Three novel 
mutations in CYP21 gene in Brazilian patients with the classic form of 21-hydroxylase 
deficiency due to a founder effect. J Clin Endocrinol Metab 2002; 87: 4314-17. 
ARTIGO 2 
44 
21. Mota ER, Bachega TA, Nishi MY, Mendonca BB, Pinto EM Comparison between Southern 
Blot and Multiplex Ligation Probe amplification techinques for detection of large 
rearrangements involving CYP21 genes in patients with 21- hydroxylase deficiency. Program 
of the Annual Meeting of the Endocrine Society, San Francisco, SF, 2008; pp 500.  
22. Carvalho VM, Nakamura OH, Vieira JG. Simultaneous quantification of seven endogenous C-
21 adrenal steroids by liquid chromatography tandem mass spectrometry in human serum. J 
Chromatrogr B Analyt Technol Biomed Life Sci, 2008; 872: 154-61. 
23. Lajic S, Clauin S, Robins T, Vexiau P Blanché H, Bellanne-Chantelot C, Wedell A Novel 
mutations in CYP21 detected in individuals hyperandrogenism. J Clin Endocrinol Metab 2002; 
87: 2824-29 
24. Wilson RC, Nercado AB, Cheng KC, New MI Steroid 21-hydroxylase deficiency: genotype 
may not predict phenotype J Clin Endocrinol Metab 1995; 80: 2322-29. 
25. Barbat B, Boguo A, Raux- Demay MC, Kuttenn F, Boue J, Simon- Bouy B, Serre JL, Mornet E  
Screening of CYP21 gene mutations in 129 french patients affected by steroid 21- hydroxylase 
deficiency. Hum Mutat 1995; 5: 126-30. 
26. Wilson RC, Nimkarn, S Dumic M, Obeid J, Azar MR, Najmabadi H Saffari F, New MI. 
Ethnic- specific distibuition of mutations in 716 patients with congenital adrenal hyperplasia 
owing to 21- hydroxylase deficiency Mol Genet Metabol 2007; 90: 414-21. 
27. Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman H . Mutational spectrum of the steroid 
21- hydroxylase gene in Sweden: implications for genetic diagnosis and association with 
disease manifestations J Clin Endocrinol Metab1994; 78: 1145-52. 
28. Bobba A, Marra E, Giannattasio S, Iolascon A, Monno F, Di Maio S (1999) 21-hydroxylase 
deficiency in Italy: a distinct distribuition pattern of CYP21 mutations in a sample from 
southern Italy. J Med Genet 1999;36: 648-50. 
29. Bachega TA, Billerbeck AE, Parente EB, Lemos- Marini SH, Baptista MT, Mello MP,  Guerra 
G Jr, Kuperman H, Setian N, Damiani D,  Torres N, Castro M, Menconca BB. Multicentric 
Study of Brazilian with 21- hydroxylase deficiency: A genotype- phenotype correlation Arq 
Bras Endocrinol Metabol 2004; 48: 697-704. 
30. Araújo RS, Mendonca BB, Barbosa AS, Lin CJ, Marcondes JA, Billerbeck AE, Bachega TA 
Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical 
form of 21-hydroxylase deficiency. J Clin Endocrinol Metab; 2007: 92, 4028-34. 
ARTIGO 2 
45 
31. Deneux C, Tardy V,  Dib A, Mornet E,  Billaud L,  Charron D, Morel Y, Kuttenn F Phenotype-
Genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21- 
hydroxylase deficiency. J Clin Endocrinol Metab 2001; 86: 207-13. 
32. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin 
Endocrinol Metab 1994; 78: 810-15.  
33. Azziz R, Dewailly D, Diagnosis, screening, and treatment of nonclassic 21-hydroxylase 
deficiency. In Androgen excess disorders in women (eds. Azziz R, Nestler JE, Dewailly D), 
Lippincott-Raven, Philadelphia; 1997. p.181-92. 
34. Witchel SF, Aston CE .The role of heterozigozity for CYP21 in the polycystic ovary syndrome.  
J Pediatr Endocrinol Metab 2000; 13 (supp 5), 1315-17. 
35. New MI, Lorezen F, Lerner AJ, Khon B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy 
DJ, Pang S, Levine LS Genotyping steroid 21-hydroxylase deficiency: hormonal reference 
data. J Clin Endocrinol Metab1983; 92: 4028-34. 
36. New MI Extensive clinical experience: Nonclassical 21-hydroxylase deficiency. J Clin 
Endocrinol Metab 91; 2006: 4205-14.  
37. Blanché H,  Vexiau P, Clauin S, Le Gall I, Fiet J, Mornet E, Dausset J, Bellané-Chantelot C 
Exhaustive screening of 21-hydroxylase gene in a population of hyperandrogenic women. Hum 
Genet 1997; 101: 56-60. 
38. Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, Miller WL .The common P450 
oxidoreductase variant A503V is not a modifier gene for 21- hydroxylase deficiency. J Clin 
Endocrinol Metab 2008; 93: 2913-2916.  
  
ARTIGO 2 
46 
Table 1. Frequency of CYP21A2 gene mutations found in unrelated alleles of 45 patients with the 
SW, SV and NC forms of 21OHD, and in the affected allele of 62 obligatory carriers. 
CYP21A2 Affected: Phenotype / Clinical forms   Carrier state 
Mutations SW SV NC Total (%) Total (%) 
I2 splice 17 1 0 18 20.5 12 19.4 
V281L 0 0 16 16 18.2 10 16.1 
R356W 10 0 0 10 11.4 9 14.5 
I172N 0 8 0 8 9.1 4 6.5 
Q318X 5 0 0 5 5.7 5 8.1 
Conv 5 0 0 5 5.7 4 6.5 
Deletion 4 1 0 5 5.7 5 8.1 
Cluster 2 1 0 3 3.4 3 4.8 
1003^1004 insA 1 0 0 1 1.1 1 1.6 
C168 lΔ1nt 1 0 0 1 1.1 0 0.0 
F306+1nt 1 0 0 1 1.1 0 0.0 
InsT 0 1 0 1 1.1 1 1.6 
R408C 0 1 0 1 1.1 1 1.6 
IVS2-2 A>G 0 0 1 1 1.1 0 0.0 
P30L 0 0 1 1 1.1 0 0.0 
 IVS2+5 G>A, V281L 1 0 0 1 1.1 1 1.6 
R356W, Q318X, InsT 1 0 0 1 1.1 1 1.6 
I2 splice, V281L 1 0 0 1 1.1 1 1.6 
R356W, Q318X 1 0 0 1 1.1 1 1.6 
I172N, V304M 0 1 0 1 1.1 1 1.6 
I2 splice, InsT 0 1 0 1 1.1 1 1.6 
I172N, V281L 0 1 0 1 1.1 1 1.6 
P30L, Cluster 0 0 1 1 1.1 0 0 
None found 0 0 3 3 3.4 0 0 
Total 50 16 22 88 100.0 62 100.0 
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Table 2: Genotype categories according to the residual enzymatic activity in classic and NC 
21OHD patients (see text for details).   
    Group A (n= 25)       Group B (n= 8) 
sex clin.form Genotype   Sex clin.form Genotype 
F SW Conv / Conv   F SV I172N / Cluster 
M SW Conv / Conv   F SV I172N / Del 
F SW Conv / Cluster   F SV I172N / I172N 
F SW Del / Del   M SV I172N / I172N 
F SW I2 splice / 1003^1004 insA   F SV I172N / I2 splice, InsT  
M SW I2 splice / C168 delΔ1+I4nt   F SV I172N / R408C 
M SW I2 splice / Del   M SV I172N, V281L / I2 splice  
F SW I2 splice / F306+1nt   F SV I172N, V304M / InsT 
F SW I2 splice / I2 splice      
F SW I2 splice / I2 splice      
F SW I2 splice / I2 splice       Group C (n= 12) 
M SW I2 splice / I2 splice   Sex clin.form Genotype 
M SW I2 splice / IVS2+5 G>A, V281L      
M SW I2 splice / Q318X   F NC P30L / P30L, Cluster 
F SW I2 splice / R356W   F NC V281L / IVS2-2 A>G 
M SW I2 splice / R356W   M* NC V281L / I2 splice 
F SW I2 splice / R356W, Q318X, InsT   M* NC V281L / R356W 
F SW Q318X / Q318X   F NC V281L / V281L 
F SW Q318X / Q318X   F NC V281L / V281L 
F SW R356W / Deletion   F NC V281L / V281L 
F SW R356W / I2 splice, V281L   F NC V281L / V281L 
F SW R356W / R356W   F NC V281L / V281L 
F SW R356W / R356W   F NC V281L / V281L 
F SW R356W / R356W   F NC V281L / (IVS5-2 A>G)?? 
F SW R356W, Q318X / Cluster   F NC ?? / ?? 
* Fathers of affected patients found to be asymptomatic NC during molecular evaluation.  
?? No mutations found or functional studies not completed.  
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Table 3. Basal and post-ACTH serum levels of 21DF and 17OHP (median and interquartile 
interval) in 21OHD patients and carriers grouped according to the CYP21A2 gene mutation (see 
text for details). 
 21-DF (ng/dL) 17OHP (ng/dL) 
Genotype Basal Post-ACTH Basal Post-ACTH 
21OHD Affected Patients     
Group A (12) 739* 
373-1,500 
876 
642-1,548 
15-661* 
5,314-18,346 
15,182* 
9,413-17,585 
Group B (6) 329 
180-619 
725 
380-1,719 
8,827 
6,866-10,933 
13,348 
8,111-15,303 
Group C (11) 158 
99-203 
1,200 
737-2,425 
910 
853-1,259 
6,566 
4,415-7,630 
21 OHD Carriers (62) 17 
17-17 
82 
51-126 
65 
33-115 
303 
216-497 
*p<0.05 vs Group C patients 
 
 49 
 
 
 
 
 
 
 
4. Artigo 3 
Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 21-
hydroxylase deficiency: further characterization of classic and  nonclassic 
patients and  heterozygote carriers  
Costa-Barbosa FA, Carvalho VM, Nakamura OH, Bachega TA, Vieira JGH, 
Kater CE. 
Eur J Endocrinol (submetido 2009) 
 
ARTIGO 3 
50 
 
 
Body: 06-Jul-2009 
 
Dear Prof. Kater, 
 
Your manuscript entitled 'Zona fasciculata 21-hydroxysteroids and precursor-to-
product ratios in 21-hydroxylase deficiency: further characterization of classic and 
nonclassic patients and heterozygote carriers' has been successfully submitted 
online and is presently being given full consideration for publication in the 
European Journal of Endocrinology. 
 
Your manuscript ID is EJE-09-0549 
 
Please mention the above manuscript ID in all future correspondence or when 
calling the office for questions. If there are any changes in your street address or 
e-mail address, please log in to Manuscript Central at 
http://mc.manuscriptcentral.com/eurjendocrinol and edit your user information 
as appropriate. 
 
You can also view the status of your manuscript at any time by checking your 
Author Centre after logging in to http://mc.manuscriptcentral.com/eurjendocrinol 
. 
 
Thank you for submitting your manuscript to the European Journal of 
Endocrinology. 
 
Yours sincerely, 
European Journal of Endocrinology Editorial Office 
 
BioScientifica Ltd 
Reg. in England no. 3190519 
 
Euro House 
22 Apex Court 
Woodlands, Bradley Stoke 
Bristol BS32 4JT 
United Kingdom  
Date Sent: 06-Jul-2009  
 
 
 
ARTIGO 3 
51 
 
 
 
Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 
21-hydroxylase deficiency: further characterization of classic and nonclassic  
patients and heterozygote carriers 
 
Flávia A. Costa-Barbosa, Valdemir M. Carvalho, Odete H. Nakamura,  
Tânia A.S.S. Bachega, José Gilberto H. Vieira & Claudio E. Kater 
 
Steroids Laboratory, Adrenal and Hypertension Unit, Division of Endocrinology, Department of 
Medicine, Federal University of São Paulo, UNIFESP-EPM, São Paulo, Brazil (FAC-B, JGHV, 
CEK), Fleury Institute, São Paulo, Brazil (VMC, ON, JGHV), and Endocrinology and 
Development Unit, Division of Endocrinology (LIM-42), Hospital das Clínicas, University of São 
Paulo School of Medicine, São Paulo, SP, Brazil (TASSB).  
 
 
Running title: S, DOC, and B profile in 21OHD  
 
Key words: 11-deoxycortisol (S), 11-deoxycorticosterone (DOC), corticosterone (B), 21-
deoxycortisol (21DF), 21-hydroxylase deficiency (21OHD).   
 
 
ARTIGO 3 
52 
Corresponding author: Claudio E. Kater 
Associate Professor of Medicine, Steroids Laboratory 
Division of Endocrinology, Dept. of Medicine, Federal University of São Paulo 
Rua Pedro de Toledo, 781 – 13o. andar 
04039-032 São Paulo, SP – Brazil 
Tel/FAX: 55-11-5574-6502 
e.mail: kater@unifesp.br 
 
Word count: 2254 
 
Disclosure Statement: The authors have nothing to disclose 
 
ARTIGO 3 
53 
Abstract 
Introduction: Although much is known about the increased levels of the 21-hydroxylase substrates 
17-hydroxyprogesterone (17OHP) and 21-deoxycortisol (21DF) - the biochemical markers of all 
forms of 21-hydroxylase deficiency (21OHD), only limited information is available on the zona 
fasciculata (ZF) 21-hydroxysteroids: 11-deoxycortisol (S), 11-deoxycorticosterone (DOC) and 
corticosterone (B), products distal to the enzymatic block. Objective: To investigate whether basal 
and post-ACTH levels of S, DOC, and B and the 21-hydroxylase precursor-to-product ratios 
determined by LC-MS/MS  could disclose distinct profiles in genotypically confirmed classic 
(n=14) and nonclassic (NC; n=12) patients, heterozygote carriers (n=62) and wild-types (WT; 
n=26) for 21OHD. Results: Salt wasting (SW) and simple virilizing (SV) classic 21OHD patients 
had high basal levels of DOC with no further increase in response to ACTH. Stimulated DOC was 
similar in 21OHD patients and carriers, but reduced as compared to WT. ACTH-stimulated B 
increased gradually from SW and SV through WT. The post-ACTH 21DF/B ratio was able to 
identify 92% of the carriers. All NC patients could be identified by post-ACTH 17OHP/DOC and 
21DF/B, with no overlap with carriers. Conclusion: Although 21-hydroxylase is a key step in both 
17-hydroxy and 17-deoxy pathways of ZF, the reaction is mostly affected in the latter pathway, 
leading to a significant impairment of B production, which may further characterize the 21OHD 
subtypes. Basal DOC levels are elevated in SW patients probably as a result of extraadrenal 
production from increased progesterone. Finally, the use of specific precursor-to-product ratios are 
informative and may additionally characterize 21OHD patients and carriers.  
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Introduction 
21-hydroxylase deficiency (21OHD) is the most frequent autosomal recessive disorder 
in humans. If not rapidly diagnosed, the salt-wasting form (SW) is a life-threatening condition that 
manifests several weeks after birth by acute adrenal insufficiency (lack of cortisol and aldosterone), 
whereas in the simple-virilizing (SV) form sufficient aldosterone is produced to prevent salt loss. In 
both classic forms, prenatal exposure to increased androgen levels result in ambiguous genitalia in 
the female and macrogenitosomia in the male newborn. In the milder nonclassic (NC) form, 
cortisol production is normal at the expense of increased ACTH levels, which in turn result in 
clinical hyperandrogenism (acne, hirsutism, menstrual abnormalities, infertility), manifested from 
childhood through early adult life 
(1,2)
. 
Although much is known about the increased levels of the 21-hydroxylase steroid 
substrates, progesterone, 17-hydroxyprogesterone (17OHP) and 21-deoxycortisol (21DF) - 
biochemical markers of 21OHD 
(3,4)
 - few detailed information is available on the zona fasciculata 
(ZF) 21-hydroxylated products distal to the enzymatic block: 11-deoxycortisol (S), 
deoxycorticosterone (DOC) and corticosterone (B) 
(5,6)
.  
A host of CYP21A2 gene mutations determine the severity of the enzymatic activity in 
both ZF and zona glomerulosa (ZG) of the adrenal cortex, resulting in characteristic steroid profiles 
for all forms of 21OHD. Residual enzymatic activity from the less impaired allele may be 
associated with virtually normal mineralocorticoid production in mild and moderate forms 
(1,7)
. In 
addition, previous studies in these patients have shown decreased levels of cortisol, S, and B (21-
hydroxylated steroids from both the 17-hydroxy and 17-deoxypathways of ZF) 
(3,5-8)
. 
Use of the ACTH-stimulated 17OHP levels to discriminate the heterozygote carrier 
population (referred herein simply as “carriers”) from NC 21OHD and from normal subjects can be 
challenging. In fact, the several cutoff levels proposed to differentiate carriers from NC and normal 
subjects show significant overlaps between these groups 
(8-11)
. Therefore, ACTH-stimulated 21DF 
levels and/or specific precursor-to-product ratios (17OHP:S and 17OHP:18OHDOC) have been 
proposed as diagnostic tools to identify carriers for 21OHD 
(12,13)
.     
In this study, we employed tandem mass spectrometry after HPLC separation to 
examine baseline and ACTH-stimulated serum levels of the steroids distal to the 21-hydroxylase 
block - S, DOC, and B -, in classic (SW, SV) and NC patients with 21OHD, carriers and wild-types 
(WT) for the disease. We also investigated whether specific precursor-to-product ratios could be a 
useful diagnostic tool in distinguishing 21OHD carriers from normal subject (WT), and NC 
patients from carriers. 
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Subjects and Methods 
The study group included: (a) 26 affected patients with 21OHD: 9 SW (4M/5F; 1-
23y), 5 SV (1M/4F; 8-28y), and 12 NC (2M/10F; 4-42y), whose phenotypes were ascertained by 
clinical and biochemical data, and confirmed by genotyping; (b) 62 genotypically confirmed 
obligatory carriers of classic (n= 52; 25M/27F; 23-62y) and NC 21OHD (n= 10; 3M/7F; 29-45y), 
and (c) 26 genotypically normal control subjects (21-hydroxylase “wild-types” [WT]; 11M/15F; 
23-65y).  
Patients who were on replacement therapy had their medications withheld for 48h 
before the study. None of the subjects reported the recent use of any medications that could 
potentially interfere with the study parameters. All subjects were submitted to an ACTH 
stimulation test (Synacthen
®
, Novartis, 250 μg IV bolus) after overnight fasting and 30’ 
recumbence, with blood samples drawn at 0’ (between 0800h and 0900h) and 60’ after injection. 
Premenopausal women were studied in the early follicular phase (days 2 to 5) of the menstrual 
cycle. 
The study protocol was previously approved by the Committees on Human Research 
of all involved institutions and informed written consent was obtained from all subjects and/or legal 
responsible. 
 
Hormonal assays 
Serum S, DOC, B, 17OHP, and 21DF were simultaneously determined in each sample 
by tandem mass spectrometry preceded by HPLC separation (LC-MS/MS), according to a 
previously described method 
(14)
. 17OHP and 21DF values are to be reported on a separate 
publication. The intra- and inter-assay coefficients of variation for S, DOC, and B were 
respectively: 10.4% and 12.1%, 8.4% and 12.5%, and 7.8% and 7.8%. Quantification limits for 
these steroids were: 15 ng/dL, 10 ng/dL, and 95 ng/dL, respectively. To convert metric (ng/dL) to 
SI units (nmol/L) multiply S or B by 0.0289 and DOC by 0.0303. 
 
Precursor-to-product ratios 
Individual values of specific precursor-to-product ratios were calculated by dividing 
basal and post-ACTH 17OHP and 21DF by S, DOC, and B. 17OHP/B and 21DF/B were multiplied 
by 10 and 10
2
, respectively. The ratios are unitless since all steroids are reported in ng/dL.  
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Molecular analysis 
All 21OHD patients, carriers and WT have been previously genotyped and the results 
will be reported elsewhere. 
 
Statistical analysis 
The “R Project of Statistical Computing” version 2.8.1 (hosted by Department of 
Statistics and Mathematics, Vienna University, Austria -www.r-project.org) was used for 
calculations. The nonparametric multiple comparison test of Kruskal-Wallis, was used for 
comparisons between groups. Receiver operator characteristics (ROC) curves were used to define 
cutoff points for ACTH-stimulated 21DF and 17OHP over S, DOC and B ratios in order to separate 
21OHD carriers, NC, and WT. For statistical purposes all values below the quantification limit for 
any of the steroids were arbitrarily considered equal to the quantification level divided by the 
square root of 2 (therefore defining an average number for all undetectable values). The level of 
statistical significance was set up at 5% (p<0.05). 
 
Results 
Table 1 depicts the mean±SE and the median plus the interquartile interval (IQI) of 
serum S, DOC and B for classic (SW and SV) and NC 21OHD patients, carriers and WT. 
 
11-Deoxycortisol 
Basal S levels were reduced and ACTH-unresponsive in SW 21OHD; both values 
were significantly lower than in the other groups. Although higher than in SW, basal S levels were 
also ACTH-unresponsive in SV patients. Except for higher basal values in NC patients, basal and 
post-ACTH S levels were similar among NC patients, carriers and WT.  
 
11-Deoxycorticosterone 
Basal DOC levels were higher in SW patients than in all the other groups (but 
significantly only against carriers). However, DOC responses to ACTH stimulation were abolished 
in both SW and SV patients and significantly impaired in NC and carriers, as compared to WT.  
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Corticosterone 
Compared to WT, basal B levels were slightly reduced in all other groups (but 
significantly only for carriers). However, B responses to ACTH were virtually abolished in classic 
and reduced in NC patients and carriers, as compared to WT.  
The significant overlap (75% to >90%) observed for the individual basal and post-
ACTH levels of S, DOC, and B among 21OHD NC, carriers and WT precluded discrimination 
between these groups. 
 
Ratios of 17OHP and 21DF over S, DOC, and B (figures 1 and 2) 
Because basal levels of 17OHP and 21DF are already markedly increased in classic 
patients with 21OHD, the precursor-to-product ratios are of little additional value for diagnostic 
purposes. Therefore, these ratios (in particular the ACTH-stimulated ones) were applied mainly to 
differentiate 21OHD carriers from WT and NC patients from carriers. 
 
Separating 21OHD carriers from WT 
Table 2 shows the cutoff points, areas under the curve (AUC), sensitivity, specificity, 
and overlap for the 17OHP and 21DF over S, DOC, and B ratios, for carriers versus WT. For 100% 
specificity, the sensitivities of the 17OHP ratios were: 61% (for a cutoff ratio of 2.67), 16% (cutoff 
ratio of 37.2), and 35% (cutoff ratio of 0.24), respectively, whereas those of the 21DF ratios were 
76% (cutoff ratio of 0.44), 79% (cutoff ratio of 24.4), 92% (cutoff ratio of 1.53), respectively. 
Overall the ratios that employed the 21DF as the numerator offered a better discrimination, and 
among them, the 21DF/B ratio was the best to separate carriers from WT, with 91.9% sensitivity 
and 100% specificity. 
 
Separating NC patients from carriers 
Table 2 also shows the cutoff points, areas under the curve (AUC), sensitivity, 
specificity, and overlap for the 17OHP and 21DF over S, DOC, and B ratios, for NC patients 
versus carriers. As anticipated, the separation of NC patients from carriers is simpler, and although 
all gave a good performance, the 21DF/B and the 17OHP/DOC ratios had both 100% sensitivity 
and specificity. 
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Discussion 
Different from precursor products, steroids distal to the enzymatic block are seldom 
investigated in congenital adrenal hyperplasia. They may, however, be additional diagnostic tools 
by themselves or when analyzed in combination with the respective precursor steroid, as precursor-
to-product ratios. In 21OHD, it is expected that synthesis of B, DOC, S, and F are all impaired in 
the adrenal ZF due to the enzymatic blockade, which in turn results in increased production of 
17OHP and 21DF. In this paper we employed LC-MS/MS to examine basal and post-ACTH serum 
levels of S, DOC, and B, and their quotient (ratio) under 17OHP and 21DF levels in classic and NC 
patients with 21OHD, carriers and normal subjects (WT for the disease) in an attempt to further 
improve the discrimination of these groups. 
Aside from the classic SW patients, all other groups are unremarkable regarding basal 
levels of S and B that were not significantly different from WT. However, their responses to 
additional ACTH stimulation were invariably blunted in SW and SV patients, and otherwise 
normal to slightly impaired in NC and carriers. The normal to slightly increased basal values of S 
in SV and NC, and especially DOC in SW and SV, could be justified in several ways: (a) as a result 
from reduced efficiency of 11 -hydroxylation due to increased androgen levels acting as 
pseudosubstrates, as previously suggested 
(15,16)
; (b) due to residual 21-hydroxylase activity in the 
ZF biosynthetic pathways, associated to milder CYP21 gene mutations; (c) due to extraadrenal 21-
hydroxylation of progesterone 
(17-19)
. 
Teleologically, the increased levels of DOC observed in the SW patient is a metabolic 
effort to conserve salt in the newborn period, a mechanism that is usually inefficient; interestingly, 
several of these patients lead a normal adult life without the need of mineralocorticoid 
replacement 
(20)
. Past studies have suggested the adrenal ZG as the origin of DOC in classic 
21OHD since its production is renin-angiotensin responsive (increase in response to upright posture 
and suppress following salt loading), in contrast to its normal ACTH-dependence in the ZF 
(6,21-23)
. 
Later on, several tissues were shown to perform CYP21- independent 21-hydroxylation 
(20,24,25)
, and 
recently it has been demonstrated that hepatic CYP2C19 and CYP3A4 are able to convert 
progesterone to DOC, although less efficiently (10-17%) than 21-hydroxylase 
(26,27)
. 
Our results demonstrate that unlike S and DOC, B unveils a spectrum of ACTH 
responses in the study groups, from slight impairment in carriers throughout virtual obliteration in 
SW patients (table 1), indicating the progressive damage to 21-hydroxylation in the ZF 17-
deoxypathway 
(5,21)
. Overall, the basal and post-ACTH levels of the steroids distal to the 21-
hydroxylase block are not sufficient per se to be used as additional diagnostic markers of the 
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disease, mostly because of their significant overlaps. In this respect, B seems the best distal-to-the 
block steroid to identify 21OHD subgroups. 
Because S, DOC, and B could not precisely characterize 21OHD subgroups, we used 
precursor-to-product ratios in order to improve diagnostic accuracy, particularly for distinguishing 
carriers from WT and NC patients from carriers.  
21DF is an 11 -hydroxy-derivative of 17OHP that was shown to be an important 
additional marker of 21OHD, both for patients and carriers 
(3,28)
. Thus, we contemplate that 
precursor-to-product ratios employing 21DF instead of 17OHP could be of better diagnostic value. 
Our data demonstrate that the post-ACTH 21DF ratios (particularly 21DF/B) surpass those using 
17OHP in order to detect carriers among genotypically normal subjects (WT), confirming previous 
results that ACTH-stimulated 21DF is superior to 17OHP in differentiating these groups 
(28-30)
.  
Also, in vitro studies indicate that the 17-hydroxylation of progesterone proceeds three 
times faster than its 21-hydroxylation, providing more substrate to the 17-hydroxy- than to the 17-
deoxy-pathway of ZF 
(31)
. Therefore, the 21DF/DOC and 21DF/B ratios would be more robust 
diagnostic tools than 21DF/S to separate 21OHD subgroups. 
Although previous studies have shown a clear-cut separation of carriers from “normal 
controls” using post-ACTH 17OHP/DOC ratio (13), our data disclose an important overlap of 84% 
between carriers and WT. In a similar study, Pardini et al detected 94% of 21OHD carriers using 
the ratio of 17OHP to a more distal-to-the block product, 18-hydroxydeoxycorticosterone 
(18OHDOC) 
(12)
. However, the availability to measure this steroid is limited. But since 18-
hydroxylation and 11 -hydroxylation of DOC are performed by a single enzyme - CYP11B1 -, B 
would be equivalent to 18OHDOC for this purpose; yet, our data show that the 17OHP/B ratio was 
as weak as 17OHP/DOC (65% and 84% overlap, respectively), even when outliers are excluded 
(remaining 24% and 26% overlap, respectively).  
Another diagnostic dilemma is the distinction of NC patients from 21OHD carriers, 
especially in the male. However, the higher basal and post-ACTH levels of 17OHP and 21DF 
appear sufficient to characterize them 
(1-3)
. Nevertheless, values of post-ACTH precursor-to-product 
ratios (in especial the 21DF/B ratio) are unambiguous in identifying all NC patients from carriers. 
This may be particularly useful in individuals with mild increases in 17OHP levels 
(8-11)
.  
In summary, the ZF 21-hydroxysteroids S, DOC, and B disclose an interesting profile 
in the 21OHD subtypes ranging from reduced to increased basal levels but with a systematic 
impaired response to ACTH stimulation. The increased basal levels of DOC and S may result from 
(a) inefficient 11 -hydroxylation due to androgen excess, (b) residual 21-hydroxylase activity due 
to specific CYP21 gene mutations, and/or (c) extraadrenal 21-hydroxylation of progesterone by 
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hepatic CYP enzymes. The selective gradual response of B to ACTH and the precursor-to-product 
ratios, particularly 21DF/B, are distinctive characteristics of 21OHD subtypes that can be used to 
assist in the separation of carriers from normal subjects and of NC from carriers.   
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Table 2. Cutoff points, areas-under-the-curves (AUC), sensitivities, specificities, and overlaps of 
the post-ACTH precursor (17OHP and 21DF)-to-product (S, DOC, and B) ratios between carriers 
versus wild-types (WT) and between nonclassic (NC) patients and carriers for 21OHD.   
 17OHP/S 17OHP/DOC 17OHP/B 
(x10) 
21DF/S 21DF/DOC 21DF/B 
(x100) 
Carriers vs WT 
Cutoff value 
AUC 
Sensitivity 
Specificity 
Overlap 
 
2.0 
0.937 
82.3% 
96.2% 
39% 
 
9.67 
0.935 
83.9% 
92.3% 
84%* 
 
0.96 
0.911 
80.6% 
92.3% 
65%* 
 
0.25 
0.927 
85.5% 
88.5% 
24% 
 
1.47 
0.951 
85.5% 
92.3% 
21% 
 
1.53 
0.975 
91.9% 
100% 
8% 
NC vs Carriers 
Cutoff value 
AUC 
Sensitivity 
Specificity 
Overlap 
 
11.2 
0.999 
100% 
98.4% 
2% 
 
75 
1.000 
100% 
100% 
0% 
 
10.5 
0.999 
100% 
98.4% 
2% 
 
1.21 
0.983 
100% 
82.3% 
5% 
 
23.2 
0.999 
100% 
98.4% 
2% 
 
30 
1.000 
100% 
100% 
0% 
* Overlap drops to 26% and 24%, respectively, after removing one outlier from each analysis. 
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Figure 1: The box-plots represent post-ACTH 17OHP over S, DOC, and B ratios in 21OHD 
subtypes: classic and nonclassic (NC) patients, carriers and WT. Bars across the box represent the 
median; the edges of the box, the 25
th
 and the 75
th
 percentiles (P25 and P75) and the error  bars, the 
10
th
 and 90
th
 percentiles (P10 and P90), respectively. 
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Figure 2: The box-plots represent post-ACTH 21DF over S, DOC, and B ratios in 21OHD 
subtypes: classic and nonclassic (NC) patients, carriers and WT. Bars across the box represent the 
median; the edges of the box,  the 25
th
 and the 75
th
 percentiles (P25 and P75) and the error  bars, 
the 10
th
 and 90
th
 percentiles (P10 and P90), respectively. 
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Principais Achados 
 Os dados desse conjunto de estudos confirmaram que o 21DF após estímulo 
pelo ACTH é superior à 17OHP na identificação de heterozigotos para a 
D21OH entre uma população de indivíduos normais. Para uma 
especificidade de 100%, níveis de 21DF após ACTH maiores do que 40 
ng/dL mostraram sensibilidade de 82% na detecção de heterozigotos para a 
D21OH, enquanto que níveis de 17OHP após ACTH maiores do que 298 
ng/dL tiveram sensibilidade significativamente menor (53%). Por outro 
lado, níveis de 21DF após ACTH maiores do que 300 ng/dL - em conjunto 
com 17OHP após ACTH maiores do que 1.700 ng/dL - permitiram melhor 
discriminação de pacientes com a forma NC da 21OH dentre os 
heterozigotos para a doença. 
  No estudo de frequência de mutações do gene da CYP21, foram 
identificadas mutações em 85 (96,6%) dos 88 alelos não relacionados 
estudados. Os únicos três alelos não identificados eram de pacientes com a 
forma NC (cujos níveis de 17OHP e 21DF basais e estimulados eram 
característicos de D21OH).  
  Diferentemente da 17OHP, os níveis de 21DF após ACTH não se 
correlacionaram com os diferentes grupos genotípicos nos pacientes com a 
D21OH. Nesta situação, a ausência de correlação pode ser devida à pequena 
população de pacientes estudados e à dosagem dos esteróides após curto 
período de suspensão do tratamento clínico. 
  Dentre os esteróides da zona fasciculada distais ao bloqueio da 21-
hidroxilase - S, DOC e B -, o melhor marcador na caracterização dos 
diferentes subtipos da D21OH foi B após ACTH,  apesar de sobreposição 
importante entre essas populações.  
  Níveis normais ou pouco elevados de DOC nos pacientes com a forma 
perdedora de sal podem denotar produção extra-adrenal desse esteróide.   
PRINCIPAIS ACHADOS, CONCLUSÕES E NOVAS DIREÇÕES 
71 
  Dentre as relações envolvendo precursores (17OHP e 21DF) e produtos (S, 
DOC, B) da 21-hidroxilase, aquelas que envolviam o 21DF (sobretudo 
21DF/B após ACTH), foram superiores à 17OHP na diferenciação de 
heterozigotos e indivíduos genotipicamente normais.  Embora pacientes 
com a forma NC já tivessem sido identificados pela 17OHP, as relações 
21DF/B e 17OHP/DOC após estímulo com ACTH separaram 100% desses 
pacientes dos  heterozigotos. 
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Conclusões e Novas direções 
 Com o uso da metodologia de LC-MS/MS, a dosagem do 21DF após ACTH 
confirmou-se superior na detecção de heterozigotos para a D21OH, podendo 
ser instrumento diagnóstico valioso durante o aconselhamento genético de 
familiares de pacientes afetados com esta condição. Sua dosagem também 
pode ser útil nos casos em que persiste dúvida diagnóstica na caracterização 
de formas NC entre heterozigotos. Além disso, a análise dos esteróides 
adrenais distais ao bloqueio da 21-hidroxilase apresenta-se como ferramenta 
adicional na propedêutica diagnóstica dos diversos subtipos de D21OH.  
 A definição de valores de corte mais acurados para o 21DF, especialmente 
após estímulo pelo ACTH, poderá ser útil na identificação de indivíduos 
com risco de heterozigose (e mesmo indivíduos portadores da forma não 
clássica assintomáticos) durante investigação de familiares para D21OH e, 
eventualmente, na população geral. 
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